日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Organoids in drug development: from predictive models to regulatory integration

类器官在药物研发中的应用:从预测模型到监管整合

Song, Xuyang; Chen, Xinrong; Chen, Qing; Wang, Hao; Zhang, Tao; Liao, Michael Z; Liu, Chunhong; Yu, Hongtao; Hao, Yanning; Gu, Guodong; Cheng, Zehua; Zhu, Zhiyao; Zhang, Yongbin; Hourigan, Suchitra K

Phase Ia study to evaluate RO7497987, a FLT3L-fragment Fc fusion protein, in healthy volunteers

在健康志愿者中评估 FLT3L 片段 Fc 融合蛋白 RO7497987 的 Ia 期研究

Iacovelli, Anthony J; Sanjabi, Shomyseh; Monemi, Sharareh; Amitai, Assaf; Decalf, Jérémie; Moussion, Christine; Liao, Michael Z; Rao, Gautham K; Getz, Jennifer; Mancuso, Michael R

How Clinical Pharmacology Can Support Clinical Trial Diversity and Inclusion

临床药理学如何支持临床试验的多样性和包容性

Liao, Michael Z; Sawant, Aarti; Corrigan, Brian; Haertter, Sebastian; Otsubo, Yasuto; Younis, Islam R; Kasichayanula, Sreeneeranj; Mehta, Rashmi

Cell and Gene Therapy: Transforming Treatment Paradigms for Patient-Centric Care

细胞和基因疗法:变革以患者为中心的治疗模式

Yi, Sojeong; Wu, Chia-Yung; McIntosh, Avery; Santaella, Maria E; Robinson, Tara M; Liao, Michael Z

Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma.

莫苏妥珠单抗在中国复发或难治性滤泡性淋巴瘤患者中的药代动力学和药效学的种族敏感性评估

Li Junyi, Liao Michael Z, Wilkins Justin, Penuel Elicia, Wang Bei, Vadhavkar Shweta, Peng Kun, Cao Junning, Li Zhiming, Zhang Ye, Li Wenjin, Li Donghang, Zhou Mingzhu, Wei Michael C, Kwan Antonia, Zhao Rong, Li Chunze, Li Chi-Chung, Turner David C

Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

来自 POLARIX 研究的 polatuzumab vedotin 在既往未接受治疗的弥漫性大B细胞淋巴瘤 (DLBCL) 患者中的群体药代动力学和暴露-反应分析

Deng, Rong; Gibiansky, Leonid; Lu, Tong; Flowers, Christopher R; Sehn, Laurie H; Liu, Qi; Agarwal, Priya; Liao, Michael Z; Dere, Randall; Lee, Calvin; Man, Gabriel; Hirata, Jamie; Li, Chunze; Miles, Dale

Patient, industry, and regulatory perspective on antibody-drug conjugates dose optimization

患者、行业和监管机构对抗体药物偶联物剂量优化的看法

Hamed, Salaheldin; Li, Chunze; Liao, Michael Z; Warwick, Lorna; Zhou, Zhu

Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX

种族敏感性评估:POLARIX 研究中,Polatuzumab vedotin 在既往未接受治疗的弥漫性大 B 细胞淋巴瘤的亚洲和非亚洲患者中的药代动力学

Liao, Michael Z; Deng, Rong; Gibiansky, Leonid; Lu, Tong; Agarwal, Priya; Dere, Randall; Lee, Calvin; Hirata, Jamie; Herbaux, Charles; Salles, Gilles; Li, Chunze; Miles, Dale

Pharmacokinetics of biologics in gastric cancer

胃癌生物制剂的药代动力学

Li, Junyi; Turner, David C; Li, Feifei; Chen, Xi; Liao, Michael Z; Li, Chunze

Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology

肿瘤过继细胞疗法的临床药理学展望

Huang, Weize; Li, Junyi; Liao, Michael Z; Liu, Stephanie N; Yu, Jiajie; Jing, Jing; Kotani, Naoki; Kamen, Lynn; Guelman, Sebastian; Miles, Dale R